Pharmaceuticals

Ischemic Heart Disease (IHD) Drugs Global Forecast: Market to Scale Up to $7.99 Billion by 2030 at 3.7% CAGR

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ischemic heart disease (ihd) drugs market from 2026–2035 with trusted insights from The Business Research Company

How is the Ischemic Heart Disease (IHD) Drugs Market size predicted to change over the forecast window of 2026–2035?

The market size for ischemic heart disease (IHD) drugs has demonstrated steady expansion in recent years. This market is projected to grow from $6.65 billion in 2025 to $6.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.7%. The historical growth can be attributed to factors such as the rising prevalence of coronary artery disease, an increasing geriatric population, heightened awareness of cardiovascular health, a high incidence of lifestyle-related risk factors, and the availability of generic drugs.

The ischemic heart disease (IHD) drugs market is projected to experience consistent expansion in the coming years. It is anticipated to grow to $7.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.7%. This expansion during the forecast period can be attributed to advancements in precision medicine, the integration of digital health solutions, increased adoption of combination therapies, the development of novel drug delivery systems, and the spread of telehealth and remote monitoring. Major trends expected throughout the forecast period include personalized cardiac therapy, advanced combination drug formulations, telemedicine-enabled cardiac care, improved cardiovascular risk prediction and monitoring, and minimally invasive drug delivery methods.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Which Drivers Are Contributing To The Expansion Of The Ischemic Heart Disease (IHD) Drugs Market?

The rising occurrence of heart failure is projected to stimulate expansion within the ischemic heart disease (IHD) drug market in the foreseeable future. Heart failure describes a persistent condition where the heart’s muscle fails to pump adequate blood to satisfy the body’s requirements for blood and oxygen. This inadequacy can result in symptoms such as exhaustion, breathlessness, and challenges with daily tasks. Medications for Ischemic Heart Disease (IHD) are crucial in managing heart failure. These treatments aid in preventing heart failure by mitigating risk factors and symptoms associated with ischemic heart disease. Specifically, Ischemic Heart Disease (IHD) drugs work by suppressing the heart’s pacemaker activity, proving advantageous for heart failure patients exhibiting reduced ejection fractions and elevated resting heart rates following a tolerated beta-blocker. For example, as reported in September 2023 by the US-based Heart Failure Society of America, 6.7 million Americans aged over 20 currently suffer from heart failure (HF), a figure anticipated to climb to 8.5 million Americans by 2030. Consequently, the growing prevalence of heart failure is propelling the development of the ischemic heart disease (IHD) drug market.

What Segment Classifications Make Up The Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

What Trends Are Driving The Growth Trajectory Of The Ischemic Heart Disease (IHD) Drugs Market?

Leading companies within the ischemic heart disease (IHD) drugs market are prioritizing the attainment of regulatory approvals and the expansion of drug indications to bolster available treatment choices and secure a larger segment of the market. For instance, in June 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the European Commission approved Camzyos (mavacamten), the first allosteric, selective cardiac myosin inhibitor for treating symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM). Also within that year, the U.S. FDA cleared a supplemental new drug application, drawing on Phase 3 VALOR HCM data which demonstrated a notable decrease in the necessity for septal reduction therapy among patients who received treatment. Consequently, this rising regulatory impetus and the broadening of labels for myosin inhibitors are propelling expansion within the IHD drug market.

Which Key Players Are Driving Competition In The Ischemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Which Region Is Projected To Lead The Ischemic Heart Disease (IHD) Drugs Market During The Forecast Period?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Ischemic Heart Disease (IHD) Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2026, By The Business Research Company

Ischemic Heart Disease Ihd Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Acute Ischemic Stroke Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Cardiovascular Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795